Wall Street brokerages predict that Savara Inc (NASDAQ:SVRA) will post earnings of ($0.52) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Savara’s earnings, with the highest EPS estimate coming in at ($0.39) and the lowest estimate coming in at ($0.65). Savara posted earnings of ($0.29) per share during the same quarter last year, which would suggest a negative year over year growth rate of 79.3%. The firm is scheduled to issue its next earnings results on Wednesday, March 11th.
On average, analysts expect that Savara will report full-year earnings of ($1.88) per share for the current financial year, with EPS estimates ranging from ($1.93) to ($1.82). For the next financial year, analysts expect that the firm will post earnings of ($1.51) per share, with EPS estimates ranging from ($1.74) to ($1.05). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Savara.
Savara (NASDAQ:SVRA) last posted its earnings results on Thursday, November 7th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.14.
Several brokerages have recently weighed in on SVRA. Evercore ISI set a $17.00 price target on Savara and gave the company a “buy” rating in a research report on Monday, August 12th. LADENBURG THALM/SH SH reaffirmed a “hold” rating and set a $1.00 target price on shares of Savara in a report on Thursday, October 3rd. Finally, Zacks Investment Research upgraded Savara from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $9.09.
NASDAQ:SVRA opened at $1.11 on Friday. The company has a market cap of $48.04 million, a P/E ratio of -0.86 and a beta of 0.27. The stock’s fifty day moving average price is $0.94 and its two-hundred day moving average price is $3.09. Savara has a 1 year low of $0.69 and a 1 year high of $11.96. The company has a debt-to-equity ratio of 0.23, a current ratio of 13.07 and a quick ratio of 13.07.
A number of hedge funds and other institutional investors have recently made changes to their positions in SVRA. Metropolitan Life Insurance Co NY bought a new position in Savara in the 1st quarter worth about $83,000. DekaBank Deutsche Girozentrale lifted its position in Savara by 67.5% during the second quarter. DekaBank Deutsche Girozentrale now owns 20,600 shares of the company’s stock valued at $50,000 after purchasing an additional 8,300 shares during the last quarter. Sullivan Bruyette Speros & Blaney LLC purchased a new position in Savara in the 2nd quarter worth approximately $38,000. GSA Capital Partners LLP bought a new position in shares of Savara in the 2nd quarter worth $206,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Savara by 31.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 78,019 shares of the company’s stock worth $185,000 after buying an additional 18,708 shares during the last quarter. Institutional investors and hedge funds own 40.42% of the company’s stock.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Further Reading: Channel Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.